Revolutionary drug-development platform integrated in the European Space Agency - MELiSSA consortium

ezCOL is a Dutch biotech company, that serves as the preferred valorization partner for all pharmaceutical IP that is generated by the European Space Agency (ESA) Melissa program. Within Melissa, around 100 researchers and engineers from 60 different research institutes are collaborating.   Our drug-development pipeline addresses several therapeutic indications, of which hypercholesterolemia is furthest developed, and in mid-preclinical stage.     


Preferred valorisation partner of MELiSSA pharmaceutical IP


ezCOL BV was established in the ESA Business Incubator in Noordwijk, The Netherlands.

Health benefits

Highly focused on the safety of new drug candidates

Our Mission

It is our mission to provide the best therapeutics to patients around the world by tapping into research activities aimed for long term humna space missions. The MELiSSA consortium focusses on life support systems in its broadest sense to enable long space flights. The mulitnational research and development activities in MELiSSA are spanning over 100 researchers at 60 different research institutes and organizations. ezCOL fosuses on the development of new drugs based on intellectual property derived from the MELiSSA consortium that has beneficial effects on human health and novel disease treatment options. 



Our Vision

Our vision is to develop state-of-the-art drugs that benefit the human race. We aim to provide society future-proof therapeutics with lowest adversity and at affordable costs. This way we bring health benefits to people and keep our health care systems viable.